Ticker Symbol: CUR
PCA3 royalty revenue triples and GCC sales start
QUEBEC CITY, March 17 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering lab services, announced a net loss of $3,440,655 or $0.08 per share for the first quarter ending January 31, 2009. These results are substantially in line with Management expectations. They reflect budgeted sales and marketing initiatives to promote the Previstage(TM) GCC Colorectal Cancer Staging Test and further product optimization activities. At the end of the quarter, cash, short-term investments and long-term investments stood at $16,593,947.
In particular, the results of the first quarter reflect non-recurrent expenses in the order of $433,000, including the severance pay for the November lay-off, and a special educational grant opportunity for DiagnoCure at the January 2009 Gastrointestinal Cancers Symposium ("ASCO GI") satellite symposium on molecular markers.
Highlights of the Quarter
During the last edition of the 2009 ASCO GI in January, DiagnoCure was selected to sponsor an independent panel of three key colorectal cancer opinion leaders, Dr. Edith P. Mitchell (
On February 18, 2009, the Journal of the American Medical Association published positive results on the prognostic value of the GCC marker, to which DiagnoCure secured exclusive worldwide diagnostic rights in 2007, and which is the marker used in the Company's Previstage(TM) GCC Colorectal Can
|SOURCE DIAGNOCURE INC.|
Copyright©2009 PR Newswire.
All rights reserved